Gut 消化· Wu, D., Zhu, C., Pan, H., Xu, H., Xu, J., Liu, Y., Wang, S., Xiao, M., Yu, X., Shi, S.·· 2026-10-07AI 评分50
整合筛选发现靶向IMPDH2可耗竭鸟嘌呤核苷酸,在临床前模型中抑制胰腺癌并增强KRAS抑制效果
Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition
AI 导读
研究团队整合全基因组CRISPR/Cas9筛选、大规模基因组依赖数据集和药物筛选,将IMPDH2确定为KRAS突变胰腺导管腺癌(PDAC)的关键分子弱点。IMPDH2的表达和活性并不由KRAS垂直通路驱动,靶向IMPDH2降解可诱导不可逆的鸟嘌呤核苷酸耗竭,在体外和体内抑制PDAC并增强KRAS抑制剂的疗效。
来源:Gut 消化 · gut.bmj.com